CD16 activator/anti-BCMA/anti-CD200 NK-cell engager (Affimed)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD16 activator/anti-BCMA/anti-CD200 NK-cell engager (Affimed)

Drug Alias Nameanti-CD16/anti-BCMA/anti-CD200 trispecific immune-cell engager (Affimed)trispecific antibody (Affimed)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A agonistsTumor necrosis factor ligand superfamily member 13 modulatorsOX-2 membrane glycoprotein modulators

TargetsLow affinity immunoglobulin gamma Fc region receptor III-ATumor necrosis factor ligand superfamily member 13OX-2 membrane glycoprotein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAffimed Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAffimed Nv

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A